FTG;; your thoughts from the recent ASH meeting,,
Garr doesn't want to much fluff-ie until the lawsuit is settled..
Maybe the new STEM owner will agree to share the patent-rights and settle the lawsuit,, then we could see some bright colorful info,, YES-NO ??
Does that mean one treatment & done,, or can there be more treatments for phase 1 ??
AND,, that's not even considering the low hanging fruit..
The Cayman cost for one stem cell treatment for one joint is 26K,, not counting the travel costs..
AND,, approx 2 BILLION people with aching joints in the world today.. Appears trial-to-market aprox 2 yrs..
And I know a doc who would gladly run the trials...
Been mia - sorry ~-,,
Concerning the 91 MOU & Tsukamota ;;
Appears the good doc's ( R-T & W ) were all of the same mind in 91,, when they agreed to ration the patent credits.. So,, to label one as a tagalong ,, Tsukamota has labeled all three as such.. That is my point,, why is she allowed.. HOWEVER--Garr should encourage her to appear at trial,, she could taint her entire group..
===== JUDGE T should get a good chuckle ,, because ;;=====
(( bnordheimer • Aug 23, 2014 7:40 AM ))
In addition, Judge Titus recognized that Tetzlaff was not an "interloper." He worked with them for 3 years and published 5 papers (some of which were published after the agreement was signed). He went on to say that Tetzlaff had "pre-existing rights" and he wondered where was STEM's evidence that the agreement was invalid"?
My concern,, is the 1991 MOU a valid agreement legally .. That would appear to require legal experts,, so how is a medical expert relevant.. Maybe that is Garr's issue...
FTG,, any ideas of how Tsukamota became an expert to the 1991 MOU,, or is the DEC 3 day about something more than the validity of the MOU agreement???
1991 Re: Technique for Proliferation of Nerve Cells for Transplantation
This letter is to indicate the allotment of interests ""to the inventors"" of the above invention:
45% - Dr. Samuel Weiss, Dept. of Pathology
45% - Mr. Brent Alan Williams, Dept. of Pathology
10% - Dr. Wolfram Tetzlaff, Dept. of Anatomy"
NIH guidance and funding for Neuralstem’s upcoming ALS registration trial ;;
NSI-566/ALS’s principal investigator shares insights into Neuralstem’s upcoming """ALS registration trial""", and just-concluded animal research on Alzheimer’s disease.
It has been an interesting week, to say the least, for stem cell researcher Eva Feldman, M.D., director of the Alfred Taubman Medical Research Institute at the University of Michigan and director of the ALS clinic at the school’s health system.
Between appointments, meetings and time in the lab, she was making tweaks suggested by the National Institutes of Health on her $5 million grant proposal for the organization to fund Phase 2b and Phase 3 human trials on patients with ALS, or Lou Gehrig’s disease.
AND,, Garr suggests ALS treatment commercialization in two years.....
See more at the CUR website..
Sentiment: Strong Buy
Pfizer expects to submit the NDA early in the third quarter of this year. This decision was based on discussions with the FDA regarding the final results of PALOMA-1, a randomized, Phase 2 trial comparing palbociclib plus letrozole versus letrozole alone in this population of patients.
Palbociclib received Breakthrough Therapy designation from the FDA in April 2013, for the first-line systemic treatment of women with advanced or metastatic ER+, HER2- breast cancer. This designation was based on interim data from the PALOMA-1 trial.
If I remember right there have been conditional NDA's after phase one trials !!!
fast,, been awhile since I have been in a courtroom,, but it use-ta-be the plaintiffs had to get at least one positive outcome from a civil trial or they could be sued for damages and costs.. Still true maybe ????
Add to the mix;;
Recently W & R sold their patent rights to STEM,, on the cheap,, which could have been an attempt to mitigate any attempt by STEM to sue them for damages.. That deal could require W & R to testify at any related trial at STEM's request,,
AND,, hopefully Dr. T has the same MINDSET as Dr Feldman...
Be nice if the Dr. Maurizio Fava peer review abstract for NSI 189 was published before the R&R -----early look very encouraging" ---